A phase Ib/II open label study of CDX-3379 a human monoclonal antibody targeting ERBB3 in combination with the MEK inhibitor trametinib in patients with advanced stage NRAS mutant and BRAF/NRAS wildtype (WT) melanoma

Brief description of study

If you have been diagnosed with an advanced melanoma with the NRAS mutation and BRAF/NRAS wildtype, you may qualify for this phase Ib/II study. The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.


Clinical Study Identifier: s17-00363
ClinicalTrials.gov Identifier: NCT03580382
Principal Investigator: Jeffrey S. Weber
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.